Alemtuzumab (Lemtrada)

OFFICE ADMINISTRATION [medical benefit]

Indications for Prior authorization:

All of the following must be met as a condition for coverage:

  • Relapsing, remitting MS (RRMS) confirmed by a neurologist

Approved for monotherapy if:

  • Patients with RRMS who are poor responders (tried/failed an adequate trial as confirmed by chart note documentation) to at least two first-line treatments (at least one injection and one oral), and Tysabri, and who develop accumulating disability despite therapy, as follows:
    • Injection therapy with interferon beta-1a (Rebif) OR interferon beta-1b (Betaseron) OR glatiramer (Glatopa or Copaxone 40mg)
    • Oral therapy with dimethyl fumarate (Tecfidera) OR teriflunomide (Aubagio) OR fingolimod (Gilenya)
    • IV therapy Tysabri (unless contraindicated)
  • For patients at risk of HIV infection: Patient is HIV negative
  • This drug may not be used in combination with any other disease modifying therapy for MS, either oral or injectable (e.g., Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Glatopa, Rebif, Tecfidera, Tysabri or mitoxantrone)

Dosing and duration of therapy:

  • Usual dosage: 12 mg/day IV on 5 consecutive days (total 60 mg); followed 12 months later by 12 mg IV daily for 3 consecutive days (total 36mg).
  • Dosage adjustment: serious infusion reaction: consider immediate discontinuation
  • Duration of therapy: total duration of therapy is 24 months
  • Concomitant therapy: administer antiviral prophylaxis (for herpetic viral infections) beginning on the first day of treatment and continue for at least 2 months after completion of alemtuzumab and until CD4+ lymphocycte count is 200/mm3 or higher.

Last review date: June 12, 2017

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar